Invivyd Announces FDA Authorization for Emergency Use of Pemgarda (Formerly VYD222) for Pre-Exposure Prophylaxis (PrEP) of COVID-19

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that Pemgarda™ (pemivibart), formerly...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials